CCR2 and neoplasm: The effects of the orally administered CCR2 inhibitor PF-04136309 in combination with leucovorin (folinic acid), fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) in patients with treatment-naive locally advanced pancreatic ductal adenocarcinoma were assessed in a phase Ib study; ultimately, 16 (49%) of 33 patients receiving FOLFIRINOX plus PF-04136309 achieved an objective tumor response, with local tumor control achieved in 32 (97%) patients [98].